Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma

BACKGROUND: Bortezomib belongs to a new class of anti-cancer agents, the proteasome inhibitors, and has documented activity in multiple myeloma and mantle cell lymphoma. Preclinical studies suggest that bortezomib has synergistic activity with rituximab, which provides a rationale for the exploratio...

Full description

Saved in:
Bibliographic Details
Main Authors: Lamm, Wolfgang, Kaufmann, Hannes, Raderer, Markus, Hoffmann, Martha, Chott, Andreas, Zielinski, Christoph, Drach, Johannes
Format: Artigo
Language:Inglês
Published: Ferrata Storti Foundation 2011
Subjects:
Original Articles
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3128220/
https://ncbi.nlm.nih.gov/pubmed/21486866
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2011.041392
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items